Aft Pharmaceuticals (ASX:AFP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Aft Pharmaceuticals (ASX:AFP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
AFT reports ongoing sales growth and R&D progress
Notice of Annual Meeting of Shareholders 2026
Update - Dividend/Distribution - AFP
AFT Pharmaceuticals updates dividend details for FY2026 with unfranked ordinary and supplementary dividends
FDA allows AFT injectable iron project clinical study
FDA approves AFT Pharmaceuticals' injectable iron Phase III clinical trial
FDA allows AFT injectable iron project clinical study
AFT Pharmaceuticals FY26 revenue up 22%, targets $300M+ in FY27 with strong global expansion and R&D pipeline
Application for quotation of securities - AFP
Capital Change Notice
Update - Dividend/Distribution - AFP
AFT Pharmaceuticals Increases FY2026 Dividend to NZD 0.0294 Per Share
Annual Meeting and Closing Date for Director Nominations
Dividend/Distribution - AFP
AFT Pharmaceuticals declares NZD 0.025 unfranked dividend for FY2026 with 33% withholding tax
Issue of unlisted options
Dividend distribution update
AFT Pharmaceuticals announces fully imputed final dividend of NZD 0.0347 per share
FY26 NZX App2
AFT Pharmaceuticals reports 22% revenue growth and 23% profit increase for FY2026
FY26 Annual Report
AFT Pharmaceuticals FY26 revenue up 22%, operating profit up 39%, targets $300m revenue in FY27 with strong R&D and sustainability focus
FY26 results presentation
AFT Pharmaceuticals FY26 revenue up 22%, targets $300M revenue in FY27 with global expansion and strong R&D pipeline
FY26 results
AFT Pharmaceuticals posts record FY26 profit, 22% revenue growth, and raises FY27 guidance
AFT Pharmaceuticals names Stuart Houliston CFO
AFT to release FY26 results